Los Angeles, USA, May 31, 2026 – The annual global premier event in nuclear medicine and molecular imaging, the 2026 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), has officially kicked off.
Under the theme Exponential Growth and Precision Diagnostics & Therapeutics, this year’s meeting brings together top global researchers, clinical experts and industry leaders to explore and showcase revolutionary advances in nuclear medicine across theranostics, artificial intelligence, targeted therapy and global collaboration. As a full-link partner for the global development of radiopharmaceuticals, United Well participates in the event with a strong lineup, featuring an exclusive exhibition area at Booth #528 to discuss the future with peers worldwide.
At the opening ceremony of SNMMI 2026, Dr. Jean-Luc Urbain, President of the Society, clearly stated that nuclear medicine has entered a new era of exponential growth driven by the synergy of imaging, therapy, artificial intelligence and clinical trials. To achieve responsible, patient-centered and sustainable development, the industry is focusing on establishing high-quality standards, advancing technology translation and promoting healthcare equity. Several prestigious awards were presented at this meeting, including the Henry N. Wagner, Jr. Annual Abstract Award and the Sanjiv 'Sam' Gambhir Pioneer Award, honoring breakthrough work in precision diagnosis and treatment of Alzheimer’s disease, neuroinflammation imaging, PET quantification methodologies and open-source tool development, highlighting the robust momentum from basic research to clinical translation. Invited lectures systematically reviewed and outlooked the prospects of core cardiology and novel probes, further reinforcing the industry’s key themes of precision quantification and multidisciplinary integration.
Against this vibrant industry backdrop, United Well leverages SNMMI, the world’s leading platform, to fully demonstrate its profound value and core capabilities as a full-link partner for global radiopharmaceutical development. The company is committed to integrating key resources for global partners and providing solid support from early-stage R&D to commercialization:
1. Building an integrated development pathway: United Well focuses on connecting critical links from stable isotope supply and advanced molecular imaging capabilities to clinical translation, building an efficient and controllable development pipeline for innovative drugs to address complex challenges in development.
2. Supporting target and indication expansion: The company specializes in supporting drug development covering a wide range of tumor types and emerging targets, with a particular focus on the collaborative advancement of theranostic solutions to meet unmet clinical needs.
3. Accelerating clinical translation: By providing professional imaging validation and pre-IND research services, United Well helps partners accelerate R&D progress and efficiently advance projects into clinical research.
4. Offering diversified global cooperation models: Through flexible commercial models such as license-in, joint development and distribution, United Well strives to be a reliable bridge for partners to achieve success in the global market, jointly address market challenges and maximize product value.
United Well deeply understands that sustained innovation stems from profound scientific research. We maintain long-term and close strategic cooperation with many top research institutions worldwide to jointly drive the exploration and application of cutting-edge radiopharmaceutical technologies. The SNMMI Annual Meeting is not only a window to showcase achievements but also a key platform to inspire idea exchange and forge partnerships. We sincerely invite all industry peers and partners to visit United Well’s booth #528 at the Los Angeles Convention Center for in-person in-depth discussions and explore potential collaboration opportunities.
From SNMMI 2024 to 2026, we have witnessed the rapid evolution of the radiopharmaceutical field. It is foreseeable that with the continuous breakthrough of technological barriers and increasingly close global cooperation, more innovative diagnostic and therapeutic approaches will benefit patients worldwide. Upholding the philosophy of “Deeply Engaged in Scientific Research, Co-creating the Future”, United Well will continue to spare no effort in the innovative R&D and clinical translation of radiopharmaceuticals, commit to building an international-standard nuclear medicine imaging and therapy center, promote the early launch of more revolutionary therapies, and fulfill our firm commitment to contributing to human health.
